Retension Pharmaceuticals Prices Upsized IPO at $12 per Share
Retension Pharmaceuticals (RTSN) priced its upsized initial public offering (IPO) at $12 per share, aiming to raise approximately $45 million in gross proceeds. The clinical-stage biopharmaceutical company is focused on developing treatments for hypertension and other cardiovascular diseases. The IPO includes the issuance of 3.75 million newly issued shares, with underwriters granted a 30-day option to purchase additional shares. This move reflects investor confidence in Retension's pipeline and its potential impact within the biopharmaceutical sector.
Topics: Biotech IPO Pharmaceuticals